Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6841 to 6855 of 7710 results

  1. Guadecitabine for untreated acute myeloid leukaemia [ID1411]

    Discontinued [GID-TA10325]

    Technology appraisal guidance
    Discontinued

  2. Ibrutinib for treating relapsed or refractory follicular lymphoma and marginal zone lymphoma [ID977]

    Discontinued [GID-TA11238]

    Technology appraisal guidance
    Discontinued

  3. Capecitabine for the treatment of advanced pancreatic cancer [ID127]

    Discontinued [GID-TA11239]

    Technology appraisal guidance
    Discontinued

  4. Pazopanib for adjuvant treatment of locally advanced renal cell carcinoma [ID1091]

    Discontinued [GID-TA11240]

    Technology appraisal guidance
    Discontinued

  5. Canakinumab and tocilizumab for treating systemic juvenile idiopathic arthritis [ID983]

    Discontinued [GID-TA11241]

    Technology appraisal guidance
    Discontinued

  6. Selumetinib for treating differentiated thyroid cancer [ID1079]

    Discontinued [GID-TA10207]

    Technology appraisal guidance
    Discontinued

  7. Everolimus for the treatment of prophylaxis of organ rejection in cardiac transplantation [ID114]

    Discontinued [GID-TAG232]

    Technology appraisal guidance
    Discontinued

  8. Nivolumab for treating recurrent glioblastoma [ID998]

    Discontinued [GID-TA10126]

    Technology appraisal guidance
    Discontinued

  9. Liposomal vincristine for treating Philadelphia chromosome-negative acute lymphoblastic leukaemia after two therapies [ID954]

    Discontinued [GID-TA11181]

    Technology appraisal guidance
    Discontinued

  10. Masitinib for previously treated moderate Crohn's disease [ID1239]

    Discontinued [GID-TA11188]

    Technology appraisal guidance
    Discontinued

  11. Exploratory work regarding the use of bevacizumab in the treatment of eye conditions [ID422]

    Discontinued [GID-TA11205]

    Technology appraisal guidance
    Discontinued

  12. Talimogene laherparepvec with pembrolizumab for treating unresectable or metastatic melanoma [ID3856]

    Discontinued [GID-TA10836]

    Technology appraisal guidance
    Discontinued

  13. Bintrafusp alfa for treating advanced biliary tract cancer after platinum-based chemotherapy [ID3874]

    Discontinued [GID-TA10768]

    Technology appraisal guidance
    Discontinued

  14. Apalutamide with abiraterone acetate and prednisone for treating metastatic hormone-relapsed prostate cancer [ID1480]

    Discontinued [GID-TA10465]

    Technology appraisal guidance
    Discontinued

  15. Durvalumab with tremelimumab for treating recurrent or metastatic squamous-cell head and neck cancer [ID1558]

    Discontinued [GID-TA10875]

    Technology appraisal guidance
    Discontinued